There are 2137 resources available
983P - Camrelizumab (C) in combination with apatinib (A) in patients with advanced hepatocellular carcinoma (RESCUE): An open-label, multi-center, phase II trial
Presenter: Jianming Xu
Session: E-Poster Display
Resources:
Abstract
984P - Sorafenib plus hepatic arterial infusion chemotherapy versus sorafenib alone for advanced hepatocellular carcinoma with major portal vein tumor thrombosis (Vp3/4): A randomized phase II trial
Presenter: Xiaodong Wang
Session: E-Poster Display
Resources:
Abstract
985P - A phase II study of camrelizumab for advanced hepatocellular carcinoma: Two-year outcomes and continued treatment beyond RECIST-defined progression
Presenter: Zhenggang Ren
Session: E-Poster Display
Resources:
Abstract
986P - Efficacy of atezolizumab (atezo) + bevacizumab (bev) after disease progression with atezo monotherapy in patients with previously untreated, unresectable hepatocellular carcinoma (HCC)
Presenter: Aiwu Ruth He
Session: E-Poster Display
Resources:
Abstract
987P - A phase Ib study of the PD-1 antagonist CS1003 plus lenvatinib (LEN) in Chinese patients (pts) with the first-line (1L) unresectable hepatocellular carcinoma (uHCC)
Presenter: Lin Shen
Session: E-Poster Display
Resources:
Abstract
988P - Safety analysis of the run-in phase (1st and 2nd cohort) of the IMMUNIB trial (AIO-HEP-0218/ass) - An open-label, single-arm phase II study evaluating safety and efficacy of immunotherapy with nivolumab in combination with lenvatinib in advanced stage HCC
Presenter: Arndt Vogel
Session: E-Poster Display
Resources:
Abstract
989P - Effects of combination therapy using lenvatinib and anti-pd-1 antibody on liver function in patients with advanced hepatocellar carcinoma
Presenter: Yinghao Shen
Session: E-Poster Display
Resources:
Abstract
990P - Updated results of a phase Ib study of regorafenib (REG) plus pembrolizumab (PEMBRO) for first-line treatment of advanced hepatocellular carcinoma (HCC)
Presenter: Peter R. Galle
Session: E-Poster Display
Resources:
Abstract
991P - Sintilimab plus IBI305 as first-line treatment for advanced hepatocellular carcinoma
Presenter: Fan Jia
Session: E-Poster Display
Resources:
Abstract
992P - Yttrium-90 glass microspheres in the treatment of early and advanced hepatocellular carcinoma: The LEGACY study
Presenter: Riad Salem
Session: E-Poster Display
Resources:
Abstract